Pfizer (NYSE:PFE) Trading Down 0.8%

Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price dropped 0.8% during mid-day trading on Wednesday . The company traded as low as $25.68 and last traded at $25.69. Approximately 28,885,313 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 33,467,946 shares. The stock had previously closed at $25.91.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent research reports. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a "buy" rating and a $36.00 target price on the stock. Argus lowered shares of Pfizer from a "buy" rating to a "hold" rating in a report on Friday, March 22nd. TD Cowen lowered shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a report on Monday. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and an average price target of $36.88.

Pfizer Price Performance

The company's fifty day moving average is $27.19 and its 200 day moving average is $28.76. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market cap of $143.86 billion, a PE ratio of 70.57, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the firm posted $1.14 earnings per share. Pfizer's revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Institutional Trading of Pfizer

Large investors have recently bought and sold shares of the company. Worth Asset Management LLC acquired a new stake in shares of Pfizer during the first quarter worth approximately $29,000. Briaud Financial Planning Inc acquired a new stake in shares of Pfizer during the third quarter worth approximately $30,000. Sanctuary Wealth Management L.L.C. acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $50,000. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer during the third quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC grew its position in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 1,047 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.